OPDIVO [US Package Insert] Bristol Myers Squibb, Princeton, NJ (2015) Google Scholar [2] TECENTRIQ [US Package Insert] Genentech, Inc., South San Francisco, CA (2016) Google Scholar [3] KEYTRUDA [US Package Insert] Merck & Co., Inc., Whitehouse Station, NJ (2018) Google Scholar [4]...
2023年4月3日,东京和华盛顿博赛尔-安斯泰来制药集团 (TSE:4503,总裁兼首席执行官:冈村直树,“安斯泰来”)和 Seagen Inc.(纳斯达克:SGEN)今日宣布,美国食品和药品管理局(FDA)加速批准enfortumab vedotin-ejfv联合pembrolizumab在美国用于治疗顺铂不耐受的局部晚期或转移性尿路上皮癌(la/mUC)的成年患者。这一加速批...
[viii] Challita-Eid PM, Satpayev D, Yang P, et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 2016;76(10):3003-13. [ix] PADCEV [package insert]. Northbrook, IL: Astellas Pharma U...
Tecentriq® (Atezolizumab) [Package Insert]; U.S. Food and Drug Administration: South San Francisco, CA, USA, 2022. Available online: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761034 (accessed on 10 May 2023). FDA Approves Atezolizumab for ...
Background: Immune checkpoint inhibitor (ICI) therapy has significantly improved outcomes across a range of malignancies. While infections are a well-known contributor to morbidity and mortality amongst patients receiving systemic chemotherapy regimens,